

**Supplemental Table 7A. Univariable Associations of Age with Biomarkers**

Univariable Biomarker*	Data Adjusted for Detection Limits				Data Adjusted and Imputed for Missingness			
	Estimate	SE	p	95% CI	Estimate	SE	p	95% CI
MPO	0.96	0.92	0.30	-0.84 to 2.75	1.10	0.90	0.21	-0.64 to 2.89
NE	1.80	0.75	0.02	0.37 to 3.33	1.80	0.75	0.02	0.37 to 3.33
S100A9	0.22	1.10	0.85	-1.96 to 2.39	0.63	1.20	0.60	-1.73 to 2.98
SRAGE	2.00	0.84	0.02	0.33 to 3.61	2.10	0.84	0.02	0.43 to 3.70
ENRAGE	1.60	0.93	0.09	-0.24 to 3.40	1.70	0.94	0.08	-0.19 to 3.49
IL1 $\beta$	0.98	0.77	0.20	-0.53 to 2.49	1.10	0.77	0.16	-0.41 to 2.61
YKL40	1.20	1.00	0.26	-0.86 to 3.18	0.66	1.00	0.52	-1.35 to 2.66
IL17A	0.74	1.70	0.67	-2.61 to 4.09	0.76	1.70	0.65	-2.55 to 4.07
PR3	0.59	0.93	0.53	-1.24 to 2.42	1.20	0.99	0.25	-0.79 to 3.09
ICAM1	-0.57	1.60	0.72	-3.69 to 2.54	0.48	1.40	0.73	-2.23 to 3.19
IL8	2.10	2.20	0.36	-2.33 to 6.49	2.10	2.30	0.36	-2.37 to 6.50
Calprotectin	-0.17	0.39	0.65	-0.93 to 0.59	-0.17	0.39	0.66	-0.93 to 0.59
MMP9	1.40	0.86	0.10	-0.24 to 3.12	1.50	0.86	0.09	-0.21 to 3.19
SLPI	-2.01	0.73	0.01	-3.45 to -0.57	-2.10	0.73	0.004	-3.58 to -0.72
IL5	3.70	2.80	0.20	-1.91 to 9.23	2.80	2.80	0.33	-2.73 to 8.25
S100A8	-1.00	1.40	0.48	-3.84 to 1.80	-1.30	1.40	0.34	-4.10 to 1.42
TARC	6.50	4.20	0.13	-1.81 to 14.7	5.60	4.10	0.18	-2.54 to 13.7
GMCSF	1.30	3.10	0.68	-4.85 to 7.41	2.20	3.50	0.54	-4.75 to 9.16
HMGB1	-0.92	1.70	0.60	-4.31 to 2.47	-1.00	1.50	0.49	-3.89 to 1.85
TNF $\alpha$	0.67	1.30	0.60	-1.84 to 3.18	0.12	1.30	0.92	-2.38 to 2.62
IFN $\gamma$	3.90	2.50	0.12	-0.96 to 8.72	3.70	2.50	0.14	-1.17 to 8.55
IL6	-1.00	1.40	0.47	-3.88 to 1.80	-1.20	1.50	0.42	-4.04 to 1.67
IL10	-0.64	1.50	0.67	-3.60 to 2.32	-0.61	1.60	0.70	-3.69 to 2.47
CRP	1.30	1.90	0.49	-2.40 to 5.04	2.30	3.40	0.51	-4.47 to 9.01

\* Abbreviations: CRP C reactive protein; ENRAGE Extracellular newly identified receptor for advanced glycation end products binding protein; GMCSF granulocyte macrophage colony stimulating factor; HMGB1 high mobility group box 1 protein; ICAM1 intracellular adhesion molecule 1; IFN $\gamma$  interferon  $\gamma$ ; IL interleukin; MMP9 matrix metallopeptidase 9; MPO myeloperoxidase; NE neutrophil elastase; PR3 proteinase 3; sRAGE soluble receptor for advanced glycation products; SLPI secretory leukoprotease inhibitor; TARC thymus and activation regulation chemokine; TNF $\alpha$  tumor necrosis factor  $\alpha$ ; YKL40 chitinase 3-like 1 protein.

60      **Supplemental Table 7B. Univariable Associations of Weight-for-Age *z*-Score with Biomarkers**

Univariable Biomarker*	Data Adjusted for Detection Limits				Data Adjusted and Imputed for Missingness			
	Estimate	SE	<i>p</i>	95% CI	Estimate	SE	<i>p</i>	95% CI
MPO	0.04	0.07	0.62	-0.11 to 0.18	0.05	0.07	0.48	-0.09 to 0.19
NE	-0.06	0.06	0.33	-0.18 to 0.06	-0.06	0.06	0.33	-0.18 to 0.06
S100A9	0.01	0.09	0.95	-0.17 to 0.18	0.04	0.10	0.67	-0.15 to 0.23
SRAGE	-0.04	0.07	0.60	-0.17 to 0.10	-0.04	0.07	0.6	-0.17 to 0.10
ENRAGE	0.07	0.08	0.35	-0.08 to 0.22	0.08	0.08	0.32	-0.07 to 0.23
IL1 $\beta$	-0.02	0.06	0.71	-0.15 to 0.10	-0.01	0.06	0.87	-0.13 to 0.11
YKL40	-0.01	0.08	0.95	-0.17 to 0.16	0.04	0.08	0.65	-0.12 to 0.20
IL17A	0.21	0.14	0.12	-0.05 to 0.48	0.25	0.13	0.067	-0.01 to 0.51
PR3	-0.06	0.08	0.41	-0.21 to 0.08	0.03	0.08	0.75	-0.13 to 0.18
ICAM1	0.26	0.13	0.04	0.01 to 0.50	0.26	0.11	0.017	0.05 to 0.48
IL8	0.12	0.18	0.50	-0.23 to 0.48	0.14	0.18	0.45	-0.22 to 0.50
Calprotectin	-0.02	0.03	0.50	-0.08 to 0.04	-0.02	0.03	0.5	-0.08 to 0.04
MMP9	0.03	0.07	0.65	-0.11 to 0.17	0.04	0.07	0.61	-0.10 to 0.17
SLPI	0.06	0.06	0.35	-0.06 to 0.18	0.05	0.06	0.41	-0.07 to 0.17
IL5	0.34	0.23	0.14	-0.10 to 0.79	0.33	0.22	0.14	-0.11 to 0.78
S100A8	0.43	0.11	<0.001	0.21 to 0.64	0.41	0.11	<0.001	0.20 to 0.62
TARC	0.34	0.34	0.33	-0.34 to 1.01	0.37	0.34	0.27	-0.29 to 1.03
GMCSF	0.65	0.24	0.009	0.17 to 1.13	0.83	0.28	0.0034	0.28 to 1.37
HMGB1	0.01	0.14	0.96	-0.27 to 0.28	0.05	0.12	0.65	-0.18 to 0.29
TNF $\alpha$	0.17	0.10	0.10	-0.03 to 0.37	0.13	0.10	0.19	-0.06 to 0.34
IFN $\gamma$	0.43	0.20	0.03	0.048 to 0.82	0.40	0.20	0.045	0.01 to 0.79
IL6	0.30	0.11	0.008	0.082 to 0.53	0.30	0.11	0.0094	0.08 to 0.53
IL10	0.33	0.12	0.007	0.094 to 0.56	0.36	0.12	0.0035	0.12 to 0.60
CRP	0.06	0.15	0.67	-0.24 to 0.37	-0.14	0.28	0.62	-0.68 to 0.40

61 \* Abbreviations: CRP C reactive protein; ENRAGE Extracellular newly identified receptor for advanced glycation end products  
62 binding protein; GMCSF granulocyte macrophage colony stimulating factor; HMGB1 high mobility group box 1 protein; ICAM1  
63 intracellular adhesion molecule 1; IFN $\gamma$  interferon  $\gamma$ ; IL interleukin; MMP9 matrix metallopeptidase 9; MPO myeloperoxidase; NE  
64 neutrophil elastase; PR3 proteinase 3; sRAGE soluble receptor for advanced glycation products; SLPI secretory leukoprotease  
65 inhibitor; TARC thymus and activation regulation chemokine; TNF $\alpha$  tumor necrosis factor  $\alpha$ ; YKL40 chitinase 3-like 1 protein.

**Supplemental Table 7C. Univariable Associations of Diabetes with Biomarkers**

Univariable Biomarker*	Data Adjusted for Detection Limits				Data Adjusted and Imputed for Missingness			
	Estimate	SE	p	95% CI	Estimate	SE	p	95% CI
MPO	0.05	0.03	0.13	-0.01 to 0.11	0.05	0.03	0.14	-0.02 to 0.11
NE	0.02	0.03	0.42	-0.03 to 0.07	0.02	0.03	0.42	-0.03 to 0.07
S100A9	-0.04	0.04	0.26	-0.12 to 0.03	-0.04	0.04	0.31	-0.12 to 0.04
SRAGE	-0.03	0.03	0.26	-0.09 to 0.02	-0.02	0.03	0.41	-0.08 to 0.03
ENRAGE	0.02	0.03	0.46	-0.04 to 0.09	0.03	0.03	0.42	-0.04 to 0.09
IL1 $\beta$	-0.01	0.03	0.79	-0.06 to 0.04	-0.01	0.03	0.85	-0.06 to 0.05
YKL40	0.02	0.04	0.60	-0.04 to 0.09	0.03	0.04	0.45	-0.04 to 0.10
IL17A	-0.13	0.06	0.02	-0.24 to -0.02	-0.11	0.06	0.05	-0.22 to 0.00
PR3	0.01	0.03	0.65	-0.05 to 0.08	0.00	0.03	0.90	-0.06 to 0.07
ICAM1	-0.04	0.05	0.47	-0.14 to 0.07	-0.02	0.05	0.73	-0.11 to 0.08
IL8	0.06	0.08	0.43	-0.09 to 0.21	0.07	0.08	0.40	-0.09 to 0.22
Calprotectin	-0.002	0.01	0.90	-0.03 to 0.02	-0.00	0.01	0.91	-0.03 to 0.02
MMP9	0.01	0.03	0.85	-0.05 to 0.06	0.02	0.03	0.56	-0.04 to 0.07
SLPI	-0.03	0.02	0.26	-0.08 to 0.02	-0.02	0.03	0.34	-0.08 to 0.03
IL5	-0.18	0.10	0.07	-0.36 to 0.01	-0.19	0.10	0.06	-0.38 to 0.00
S100A8	0.02	0.05	0.74	-0.08 to 0.11	0.04	0.05	0.43	-0.06 to 0.13
TARC	-0.31	0.14	0.03	-0.58 to -0.04	-0.37	0.14	0.01	-0.64 to -0.10
GMCSF	-0.08	0.11	0.47	-0.28 to 0.13	-0.08	0.12	0.51	-0.32 to 0.16
HMGB1	-0.02	0.06	0.79	-0.12 to 0.09	-0.01	0.06	0.80	-0.12 to 0.10
TNF $\alpha$	-0.07	0.04	0.11	-0.15 to 0.02	-0.081	0.04	0.07	-0.17 to 0.00
IFN $\gamma$	-0.19	0.08	0.02	-0.35 to -0.03	-0.20	0.08	0.02	-0.36 to -0.04
IL6	-0.06	0.05	0.21	-0.16 to 0.03	-0.06	0.05	0.20	-0.16 to 0.03
IL10	-0.15	0.05	0.002	-0.25 to -0.06	-0.16	0.05	0.002	-0.26 to -0.06
CRP	0.04	0.06	0.58	-0.09 to 0.16	0.11	0.12	0.37	-0.12 to 0.34

\* Abbreviations: CRP C reactive protein; ENRAGE Extracellular newly identified receptor for advanced glycation end products binding protein; GMCSF granulocyte macrophage colony stimulating factor; HMGB1 high mobility group box 1 protein; ICAM1 intracellular adhesion molecule 1; IFN $\gamma$  interferon  $\gamma$ ; IL interleukin; MMP9 matrix metallopeptidase 9; MPO myeloperoxidase; NE neutrophil elastase; PR3 proteinase 3; sRAGE soluble receptor for advanced glycation products; SLPI secretory leukoprotease inhibitor; TARC thymus and activation regulation chemokine; TNF $\alpha$  tumor necrosis factor  $\alpha$ ; YKL40 chitinase 3-like 1 protein.

74 **Supplemental Table 7D. Univariable Associations of Prior Pulmonary Exacerbations with Biomarkers**

Univariable Biomarker*	Data Adjusted for Detection Limits				Data Adjusted and Imputed for Missingness			
	Estimate	SE	p	95% CI	Estimate	SE	p	95% CI
MPO	0.20	0.12	0.09	-0.03 to 0.44	0.21	0.12	0.08	-0.02 to 0.44
NE	0.20	0.10	0.05	0.00 to 0.39	0.20	0.10	0.05	0.00 to 0.39
S100A9	-0.26	0.15	0.08	-0.54 to 0.03	-0.26	0.16	0.10	-0.57 to 0.04
SRAGE	0.16	0.11	0.15	-0.06 to 0.38	0.16	0.11	0.16	-0.06 to 0.37
ENRAGE	0.12	0.12	0.35	-0.13 to 0.36	0.11	0.12	0.36	-0.13 to 0.36
IL1 $\beta$	0.16	0.10	0.12	-0.04 to 0.36	0.16	0.10	0.12	-0.04 to 0.36
YKL40	0.08	0.14	0.57	-0.19 to 0.35	0.04	0.13	0.79	-0.23 to 0.30
IL17A	0.15	0.23	0.50	-0.29 to 0.60	0.11	0.22	0.61	-0.32 to 0.55
PR3	0.24	0.12	0.06	-0.00 to 0.48	0.22	0.13	0.09	-0.04 to 0.47
ICAM1	0.07	0.21	0.73	-0.34 to 0.48	0.04	0.18	0.81	-0.32 to 0.40
IL8	0.48	0.30	0.11	-0.10 to 1.06	0.47	0.29	0.12	-0.11 to 1.04
Calprotectin	0.13	0.05	0.01	0.03 to 0.22	0.13	0.05	0.01	0.03 to 0.22
MMP9	0.12	0.11	0.29	-0.10 to 0.35	0.13	0.11	0.23	-0.08 to 0.35
SLPI	-0.18	0.10	0.07	-0.38 to 0.01	-0.19	0.10	0.06	-0.38 to 0.00
IL5	-0.16	0.38	0.68	-0.90 to 0.58	-0.14	0.37	0.70	-0.88 to 0.59
S100A8	-0.26	0.19	0.17	-0.63 to 0.11	-0.29	0.18	0.12	-0.65 to 0.07
TARC	-0.96	0.56	0.09	-2.05 to 0.14	-0.73	0.53	0.17	-1.77 to 0.32
GMCSF	-0.00	0.41	1.00	-0.81 to 0.81	-0.11	0.46	0.82	-1.02 to 0.80
HMGB1	0.47	0.22	0.03	0.04 to 0.90	0.51	0.21	0.02	0.10 to 0.92
TNF $\alpha$	-0.20	0.17	0.24	-0.53 to 0.13	-0.18	0.17	0.28	-0.51 to 0.15
IFN $\gamma$	-0.15	0.33	0.64	-0.80 to 0.49	-0.15	0.33	0.65	-0.79 to 0.50
IL6	-0.26	0.19	0.18	-0.63 to 0.12	-0.25	0.19	0.20	-0.62 to 0.13
IL10	-0.41	0.20	0.04	-0.80 to -0.03	-0.40	0.20	0.05	-0.80 to -0.01
CRP	0.32	0.25	0.20	-0.17 to 0.80	0.18	0.45	0.69	-0.70 to 1.06

75 \*Abbreviations: CRP C reactive protein; ENRAGE Extracellular newly identified receptor for advanced glycation end products  
76 binding protein; GMCSF granulocyte macrophage colony stimulating factor; HMGB1 high mobility group box 1 protein; ICAM1  
77 intracellular adhesion molecule 1; IFN $\gamma$  interferon  $\gamma$ ; IL interleukin; MMP9 matrix metallopeptidase 9; MPO myeloperoxidase; NE  
78 neutrophil elastase; PR3 proteinase 3; sRAGE soluble receptor for advanced glycation products; SLPI secretory leukoprotease  
79 inhibitor; TARC thymus and activation regulation chemokine; TNF $\alpha$  tumor necrosis factor  $\alpha$ ; YKL40 chitinase 3-like 1 protein.

80

**Supplemental Table 7E. Univariable Associations of FEV<sub>1</sub>% with Biomarkers**

Univariable Biomarker*	Data Adjusted for Detection Limits					Data Adjusted and Imputed for Missingness				
	Estimate <sup>†</sup>	SE	p	95% CI	Estimate <sup>†</sup>	SE	p	95% CI		
MPO <sup>§</sup>	-6.30	1.60	<0.001	-9.38 to -3.27	-6.20	1.50	<0.001	-9.18 to -3.14		
NE <sup>§</sup>	-5.60	1.30	<0.001	-8.17 to -3.09	-5.60	1.30	<0.001	-8.17 to -3.09		
S100A9	3.10	2.00	0.13	-0.85 to 6.98	1.30	2.20	0.54	-2.94 to 5.58		
sRAGE <sup>¶</sup>	-5.20	1.50	<0.001	-8.12 to -2.36	-5.50	1.50	<0.001	-8.36 to -2.64		
ENRAGE <sup>¶</sup>	-5.30	1.60	0.001	-8.53 to -2.12	-5.40	1.60	0.001	-8.67 to -2.22		
IL1 $\beta$	-3.70	1.40	0.007	-6.41 to -1.07	-3.80	1.40	0.006	-6.48 to -1.11		
YKL40	-3.60	1.90	0.06	-7.19 to 0.08	-2.10	1.90	0.27	-5.69 to 1.57		
IL17A	-0.88	3.10	0.78	-6.96 to 5.21	-1.10	3.10	0.71	-7.18 to 4.91		
PR3	-4.10	1.70	0.01	-7.35 to -0.87	-5.40	1.70	0.002	-8.80 to -1.97		
ICAM1	-0.72	2.90	0.80	-6.37 to 4.92	-1.70	2.50	0.49	-6.71 to 3.23		
IL8	-8.00	4.00	0.05	-15.9 to -0.10	-8.00	4.00	0.051	-15.9 to -0.05		
Calprotectin	-1.60	0.69	0.02	-2.91 to -0.22	-1.60	0.69	0.024	-2.91 to -0.22		
MMP9 <sup>¶</sup>	-5.00	1.50	0.001	-7.97 to -2.09	-5.50	1.40	<0.001	-8.34 to -2.68		
SLPI <sup>§</sup>	6.40	1.20	<0.001	3.97 to 8.81	6.30	1.20	<0.001	3.87 to 8.75		
IL5	0.48	5.20	0.93	-9.69 to 10.6	1.10	5.20	0.84	-9.10 to 11.2		
S100A8	6.40	2.50	0.01	1.42 to 11.4	5.60	2.50	0.03	0.69 to 10.6		
TARC	5.00	7.80	0.52	-10.2 to 20.3	7.50	7.40	0.32	-7.06 to 22.0		
GMCSF	2.80	5.70	0.63	-8.36 to 13.9	3.90	6.40	0.54	-8.64 to 16.5		
HMGB1	0.12	3.00	0.97	-5.68 to 5.91	0.77	2.90	0.79	-5.01 to 6.55		
TNF $\alpha$	3.10	2.30	0.18	-1.41 to 7.65	3.60	2.30	0.12	-0.90 to 8.15		
IFN $\gamma$	0.81	4.50	0.86	-8.05 to 9.67	1.20	4.50	0.79	-7.69 to 10.1		
IL6	3.50	2.60	0.19	-1.66 to 8.6	3.40	2.60	0.20	-1.77 to 8.52		
IL10	5.30	2.70	0.05	0.01 to 10.5	5.50	2.80	0.05	-0.02 to 11.0		
CRP	-2.20	3.40	0.53	-8.91 to 4.61	-3.20	6.20	0.61	-15.4 to 9.05		

\* Abbreviations: CRP C reactive protein; ENRAGE Extracellular newly identified receptor for advanced glycation end products binding protein; GMCSF granulocyte macrophage colony stimulating factor; HMGB1 high mobility group box 1 protein; ICAM1 intracellular adhesion molecule 1; IFN $\gamma$  interferon  $\gamma$ ; IL interleukin; MMP9 matrix metallopeptidase 9; MPO myeloperoxidase; NE neutrophil elastase; PR3 proteinase 3; sRAGE soluble receptor for advanced glycation products; SLPI secretory leukoprotease inhibitor; TARC thymus and activation regulation chemokine; TNF $\alpha$  tumor necrosis factor  $\alpha$ ; YKL40 chitinase 3-like 1 protein. This table provides complete results using data adjusted for biomarker measurements outside the limits of detection as well as data adjusted and imputed for data missingness for main text Table 6, FEV<sub>1</sub>%.

† Linear Regression.

§ Significant with FDR = 0.001.

¶ Significant with FDR = 0.01.